Effect of Brain Biofeedback Therapy on the Improvement of Adverse Mood and Quality of Life in Patients with Mixed Anxiety and Depression Disturbance

Abstract

Objective To explore the effect of brain biofeedback therapy on the improvement of adverse mood and quality of life in patients with mixed anxiety and depression disturbance. Methods Eighty patients with mixed anxiety and depression disturbance treated in our hospital from May 2019 to September 2020 were selected as the research subjects, and they were randomly divided into observation group and control group, with 40 cases in each group. Both groups were treated with paroxetine and observation group was additionally treated with brain biofeedback therapy. The treatment lasted for 6 weeks. The Hamilton Depression Scale (HAMA), the Hamilton Anxiety Scale (HAMD) and the World Health Organization Quality of Life Scale (WHOQOL-100) scores of patients were compared between the two groups before treatment and at 2 weeks, 4 weeks and 6 weeks after treatment. Results Before treatment, there were no significant differences in HAMA, HAMD, and WHOQOL-100 scores between the two groups (P>0.05). At 2 weeks, 4 weeks, and 6 weeks after treatment, the HAMA score and HAMD score of the two groups were significantly lower than before treatment (P<0.05), and those in observation group were significantly lower than those in control group (P<0.05). In the WHOQOL-100 score table, after treatment, the scores of physical, psychological, environment and social relationships in the two groups were significantly higher than those before treatment (P<0.05). Among them, in the physical and psychological domains, the scores of observation group were significantly higher than those of control group (P<0.05) while in the domains of environment and social relationships, there was no significant difference between the two groups (P>0.05). Conclusion Brain biofeedback therapy had a significant effect on patients with mixed anxiety and depression disturbance, which could significantly improve patients’ adverse mood including anxiety and depression and ameliorate their quality of life.